SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending due to intense community discussion surrounding its high short interest and speculative potential for a gamma squeeze, fueled by a heavy volume of call options expiring in mid-April. Investors are actively debating the leadership of CEO John Jacobs and the potential for activist investor Himanshu Shah to initiate a proxy fight, as sentiment remains polarized between those anticipating a major partnership or buyout and those frustrated by persistent share price suppression.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to a convergence of bullish sentiment surrounding its post-quantum cryptography capabilities and its potential role in real-world asset tokenization. Community members are actively debating the impact of recent institutional developments and governance changes, with many highlighting the project's long-term utility as a primary driver for its potential market recovery.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The DAX is currently trending as investors scrutinize its technical structure and price action following recent volatility, with the community actively debating whether the index is establishing a long-term bottom or facing deeper corrective risks. Discussion is heavily focused on Elliott Wave signals, anchored VWAP support levels, and the broader macro implications of energy costs and industrial shifts within the German market.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors are actively debating the implications of Centurium Capital's recent acquisition of Blue Bottle, weighing potential synergies against concerns regarding conflicts of interest and corporate governance. Amidst this speculation, sentiment remains focused on the company's long-term growth trajectory, store expansion efforts, and ongoing expectations for a formal relisting on a major exchange.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as critical DeFi infrastructure, bolstered by a high-profile partnership with the U.S. Department of Commerce to provide on-chain macroeconomic data. The community is actively discussing the project's institutional adoption, its revenue-generating model featuring token buybacks, and its positioning as a leading player in the expanding Real World Asset (RWA) sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors monitor ongoing pharmaceutical tariff developments alongside potential expansion of its oncology portfolio and key clinical trial updates. While some market participants weigh long-term dividend stability and pipeline diversification against sector-wide regulatory pressures, community sentiment remains split between defensive positioning and frustration over the stock's recent price stagnation.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is gaining strong momentum as investors increasingly view the company as a critical backbone for AI-driven data center infrastructure and high-speed network expansion. The community is actively debating the stock's parabolic trajectory and aggressive valuation, with many traders closely watching for technical signals while balancing bullish long-term thesis on photonics against potential volatility risks.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors react to the company's deepening integration into AI infrastructure, underscored by significant multi-billion dollar strategic partnerships and purchase commitments from industry leaders. The community is actively debating the company's role in the photonics and optical interconnects market, balancing enthusiasm for their long-term supply agreements against concerns over valuation volatility and sector-wide competition.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure following disappointing quarterly delivery numbers, with investors increasingly divided between the company's core automotive business and its pivot toward autonomy and AI. The community is actively debating the upcoming autonomy roadmap and the broader impact of a potential SpaceX IPO, while technical traders closely monitor key support levels amid ongoing market volatility.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as it transitions into the S&P 500 index, triggering significant forced buying from passive index funds amidst a tight float. Investors and traders are actively debating whether this momentum is a sustainable long-term play fueled by AI infrastructure demand or an overextended short-squeeze driven by speculative hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biogen stated Apellis shareholders will also receive two contingent value rights as part of the all-cash deal.</li><li>This entitles Apellis shareholders to receive two payments of $2 per share, contingent on Syfovre meeting certain annual global net sales thresholds.</li><li>Biogen stated that the Apellis acquisition will add two commercialized medicines in differentiated immunology and rare diseases to its growth portfolio: Empaveli and Syfovre.</li></ul><p>Apellis Pharmaceuticals Inc. (APLS) shares soared 140% in Tuesday’s pre-market trade after Biogen Inc. (BIIB) announced that it has agreed to acquire the company in a $5.6 billion deal.</p><p>Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.</p><p>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis Pharmaceuticals</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.</p><p><a href="https://stocktwits.com/symbol/APLS">Biogen shares</a> were down nearly 3% at the time of writing.</p><p>Biogen stated that Apellis shareholders will also receive two contingent value rights (CVRs) as part of the all-cash deal, entitling the holder to receive two payments of $2 per share, contingent on certain annual global net sales thresholds for Syfovre being met.</p><h2 class="st-heading-2">What Does Apellis Bring To The Table?</h2><p>Biogen stated that the Apellis acquisition will add two commercialized medicines in differentiated immunology and rare diseases to its growth portfolio: Empaveli and Syfovre.</p><p>Syfovre is the first and only FDA-approved therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The regulator approved Empaveli in 2025 as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older.</p><h2 class="st-heading-2">Biogen Highlights Revenue, Earnings Boost From Apellis Acquisition</h2><p>Biogen stated that Empaveli and Syfovre will boost its topline immediately, noting that these two treatments achieved combined net sales of $689 million in 2025 and expect them to grow in the mid-to-high teens at least through 2028.</p><p>“Consistent with our strategy, this acquisition immediately advances Biogen’s ongoing transformation. The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio and bolsters our near-and long-term growth potential,” said Biogen CEO Christopher A. Viehbacher.</p><p>The company added that the Apellis acquisition is expected to be increasingly accretive to Biogen’s diluted earnings per share (EPS) starting in 2027. Biogen stated that it plans to update the full-year 2026 guidance when it reports its first-quarter (Q1) earnings.</p><p><a href="https://stocktwits.com/symbol/APLS">APLS stock</a> is down 32% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> is up 7%. The S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF (VB) is up 15%.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artl-bfrg-hkit-stocks-top-premarket-gainers-march-31-2026/cZEPAT9RIV2"><strong>ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Representative image of a trending stock chart.

APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen

Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.

Equity

<ul class="summary-bullets"><li>The revisions were driven by Unity Vector, the company’s AI-powered ad platform, among other factors, the company said.</li><li>The company said it is discontinuing its ironSource Ads Network, effective April 30th.</li><li>The company also said it has engaged a financial advisor to assist with the divestiture of its Supersonic game publishing business.</li></ul><p>Shares of Unity Software Inc. (U) gained 14% after-hours on Thursday after the company raised its first-quarter(Q1) &nbsp;revenue guidance, bolstered by its artificial intelligence-powered ad platform Vector.</p><p>The company also outlined plans, including divesting its game publishing business, to spur future revenue growth.</p><h2 class="st-heading-2">Fresh Guidance</h2><p>The San Francisco-based video game software development company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.unity.com/news/news-details/2026/Unity-Releases-Preliminary-First-Quarter-Results-Exceeding-Guidance-Will-Enhance-Growth-and-Profitability-by-Exiting-Non-Strategic-Ad-Businesses/default.aspx">expects</a> Q1 revenue of $505 million-$508 million, compared to its former estimate of $480 million-$490 million, and above an analyst estimate of $488.69 million, as per Fiscal AI. &nbsp;</p><p>Adjusted core profit for the period is expected to be $130 million to $135 million, compared to former guidance of $105 million to $110 million, and above the $109.40 million expected by Wall Street.</p><h2 class="st-heading-2">What’s Driving The Performance?</h2><p>The revisions were driven by Unity Vector, the company’s AI-powered ad platform, among other factors, the company said.</p><p>"Unity Vector continues to deliver robust growth each quarter, driving results meaningfully above our guidance. Today’s actions will accelerate Vector’s impact on our business, enhancing both revenue growth and profitability,” said CEO Matt Bromberg.</p><h2 class="st-heading-2">Other Key Announcements</h2><p>The company also said it is discontinuing its ironSource Ads Network, effective April 30th. After the first quarter, the company expects minimal revenue contribution from the network.</p><p>The company also said it has engaged a financial advisor to assist with the divestiture of its Supersonic game publishing business.</p><p>These changes are expected to spur revenue growth, and increased adjusted core profit, the company noted. &nbsp;</p><p>According to data from Koyfin, 18 of the 27 analysts covering Unity stock rate it ‘Buy’ or higher while nine rate it a ‘Hold’. The average 12-month price target on the stock is $32.33, representing a potential upside of about 89%.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around U stock improved from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/U">U stock</a> has fallen 22% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mdgl-stock-surges-most-in-month-on-eli-lilly-buyout-speculation/cZ3sam7RIlX">MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The Unity Software, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 2, 2025. 

Unity Software Rallies By Over 14% After Hours On Fresh Q1 Revenue Guidance Above Street Expectations

The San Francisco-based video game software development company now expects Q1 revenue of $505 million to $508 million.

<ul class="summary-bullets"><li>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis.</li><li>The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis.</li><li>The company licensed global rights to six pre-clinical siRNA programs in February for up to $4.4 billion to expand its pipeline.</li></ul><p>Shares of Madrigal Pharmaceuticals Inc. (MDGL) closed 12% higher on Thursday on buyout speculation by pharma giant Eli Lilly and Company (LLY).</p><p>The rumors originated after Madrigal featured on the Betaville <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.betaville.co.uk/betaville-intelligence/jrxmz7f0s1g9fqz992bo8ioi2lq6x3suvsc7">blog</a>, which highlights potential corporate transactions. The blog highlighted that the news is market gossip and added that it might be “total codswallop.”</p><h2 class="st-heading-2">Madrigal’s MASH Focus</h2><p>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious, progressive liver disease marked by fat accumulation, inflammation, and cell damage.</p><p>The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis. The company is also evaluating the drug for the treatment of compensated MASH cirrhosis.</p><h2 class="st-heading-2">Madrigal’s Financials</h2><p>For full-year 2025, the company reported Rezdiffra net sales of $958.4 million. There were more than 36,250 patients on Rezdiffra as of the end of 2025, the company said.</p><p>The company also licensed global rights to six pre-clinical siRNA programs from Suzhou Ribo Life Science Co. Ltd. &nbsp;and its subsidiary Ribocure Pharmaceuticals AB in February for up to $4.4 billion to expand its pipeline. The company is looking to undertake non-clinical studies for some of the candidates in 2026.</p><p>In January, the company announced an exclusive global license agreement with Pfizer for Ervogastat in yet another attempt to expand its MASH pipeline.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around MDGL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.</p><p>A Stocktwits user opined that Lilly will be a great company to care for Madrigal while adding that the buyout must value the company between $800-$1000 per share.</p><p><stembedurl>https://www.stocktwits.com/sarkar20/message/648675460</stembedurl></p><p>Another proposed the idea of the company merging with Viking Therapeutics instead. Viking is developing a drug candidate called VK2809 for MASH as well.</p><p><stembedurl>https://www.stocktwits.com/vu_jade/message/648680850</stembedurl></p><p><a href="https://stocktwits.com/symbol/MDGL">MDGL stock</a> has gained 55% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-as-retail-traders-pile-into-obesity-pipeline-bets/cZ3sB3KRIlO">VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation

The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.

Should Vanguard Small-Cap Index Fund ETF Shares (VB) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The contract is part of a U.S. Department of War effort to accelerate hypersonic flight tests, the company said.&nbsp;</li><li>The new award is the single largest launch contract in Rocket Lab’s history, bringing the total number of launches in the backlog to more than 70.</li><li>Separately, Clear Street analyst Greg Pendy on Wednesday initiated coverage of RKLB with a ‘Buy’ rating and $88 price target.</li></ul><p>Shares of Rocket Lab Corp (RKLB) edged up 3% after hours on Wednesday after the company secured a $190 million contract under which it will conduct 20 hypersonic test flights with its HASTE launch vehicle.</p><p>The contract is part of a U.S. Department of War effort to accelerate hypersonic flight tests, the company said.</p><h2 class="st-heading-2">Test Flight Timeline</h2><p>The company will now perform 20 hypersonic test flights with its HASTE launch vehicle over a four-year period. The first of the missions is slated to take place within months of contract signing, and the flights are aimed at demonstrating the company’s operational efficiency and ability to meet modern warfare demands, as per a statement.</p><p>The new award is the single largest launch contract in Rocket Lab’s history, bringing the total number of launches in backlog to more than 70 and pushing Rocket Lab’s total backlog across launch and space systems to more than $2 billion, the company said. Rocket Lab has sold 28 new launches in the first quarter of 2026 so far, including many for its Electron launch vehicle.</p><h2 class="st-heading-2">Analyst Take</h2><p>Separately, Clear Street analyst Greg Pendy on Wednesday initiated coverage of RKLB with a ‘Buy’ rating and a $88 price target.</p><p>The firm cited three growth drivers — medium-lift Neutron launch vehicle, small-lift leadership with Electron, and Space System segment which is increasingly securing prime contracts — for its rating, adding that it reinforces the company’s position as a leading integrated space operator.</p><p>Clear Street said that it sees these growth drivers leading to 35% annual revenue growth for Rocket Lab through 2030.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around RKLB stock fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/RKLB">RKLB stock</a> has risen 286% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/red-cat-stock-slips-as-q4-loss-misses-estimates/cZ37AcuRIWO">Red Cat Stock Slips As Q4 Loss Misses Estimates</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of Rocket Lab USA, Inc. is displayed on a smartphone screen.

RKLB Shares Rise On Fresh $190M Contract For Hypersonic Flights, Wall Street Buy Rating

The company will now perform 20 hypersonic test flights with its HASTE launch vehicle over a four-year period.

<ul class="summary-bullets"><li>Hims &amp; Hers stated earlier this month that the Ozempic and Wegovy offerings will be made available on its platform later in March.</li><li>The company said that all the available doses of Ozempic injections, and Wegovy pills as well as injections, will be available on the company’s platform at cash pay prices.</li><li>It said that the prices for these drugs will start at $149 a month.</li></ul><p>Hims &amp; Hers Health Inc. (HIMS) on Wednesday announced a pre-launch waitlist for Ozempic and Wegovy following a partnership with Novo Nordisk AS (NVO).</p><p>Hims &amp; Hers stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.</p><p>Interested users can join the waitlist&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://hims.com/weight-loss/waitlist">here</a> or&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.forhers.com/weight-loss/waitlist">here</a>.</p><h2 class="st-heading-2">When Will Ozempic And Wegovy Be Available On Hims &amp; Hers?</h2><p>Hims &amp; Hers stated&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">earlier this month</a> that the Ozempic and Wegovy offerings will be made available on its platform later in March.</p><p>This includes Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg and will also include Wegovy injections in doses of 1.7 mg and 2.4 mg. The Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.</p><p>The company stated that it will educate U.S. weight loss customers about their options across a wider range of FDA-approved treatments. When providers determine it is clinically appropriate, Hims &amp; Hers will help support a smooth transition to these medications, it said.</p><h2 class="st-heading-2">How Much Will Ozempic And Wegovy Cost On Hims &amp; Hers?</h2><p>Hims &amp; Hers stated that all the available doses of Ozempic injections, and Wegovy pills as well as injections, will be available on the company’s platform at cash pay prices. The telehealth platform added that prices for these drugs will start at $149 a month.</p><p>According to Novo Nordisk, Ozempic injections in doses of 0.25 mg and 0.5 mg are available at $199 per month for the first two months for new patients.</p><p>Similarly, the Wegovy pill costs $149 per month for the 1.5 mg dose, while the injection costs $199 a month for the first two months for the 0.25 mg and 0.5 mg doses.</p><p><a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 26% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">NOVO stock</a> is down 27%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 19% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF Shares (VB) is up 18%.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-trade-deficit-china-down-30-past-year-jamieson-greer/cZ37Q0wRIgZ"><strong>US Trade Deficit With China Down 30% Over Past Year, Jamieson Greer Reportedly Says: ‘It Would Be Very Helpful If…’</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk

The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.

<ul class="summary-bullets"><li>The company said it expects Bumble App Revenue of $171 million to $174 million for Q126.</li><li>In Q4, total revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter.</li></ul><p>Shares of Bumble rallied nearly 25% during Wednesday’s extended hours of trading as upbeat outlook for first-quarter revenue cushioned worries from weakness in fourth-quarter earnings.&nbsp;&nbsp;</p><p>The company said it expects total&nbsp;revenue&nbsp;for Q1 2026 to be in the range of $209 million to $213 million, which includes Bumble App Revenue of $171 million to $174 million. Analysts on average&nbsp;estimate revenue of $210 million.&nbsp;</p><p>BMBL expects adjusted core profit in the range of $76 million to $80 million for the quarter.</p><h2 class="st-heading-2">Weak Q4</h2><p>Total Revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter. Bumble App revenue also fell 14.8% to $181.0 million, compared to $212.4 million.</p><p>Bumble’s Total Paying Users slumped 20.5% to 3.3 million, compared to 4.2 million.</p><p>The company said&nbsp;its fourth quarter net loss was $611.1 million, compared to net earnings of $9.3 million from the year-ago quarter.&nbsp;</p><h2 class="st-heading-2">FY 2025</h2><p>In FY2025, Bumble’s total revenue decreased 9.9% to $965.7 million, compared to $1.07 billion. Total Paying Users decreased 11.5% to 3.7 million, compared to 4.1 million.&nbsp;</p><p>“In 2025, we made the deliberate choice to return Bumble to its women-first foundation, raising the bar on trust and authenticity while addressing pain points our members experience with online dating,” said Whitney Wolfe Herd, Founder &amp; CEO of Bumble Inc.</p><p>“With the heavy lift of our quality reset behind us, we are accelerating product innovation and prioritizing member experience enhancements. We are building from a stronger base and positioning Bumble for its next chapter of product-led growth,” Herd said.&nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around BMBL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in BMBL have fallen 2.4% year-to-date.&nbsp;</p>

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. 

Bumble Stock Is Rallying Today After Hours – What Is Causing The Bull Run?

The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million. 

<ul class="summary-bullets"><li>The aircraft in question is the first of a fleet currently in production to support the testing, Joby said.</li><li>The announcement comes on the heels of the company recently saying that it stands the chance of beginning early operations this year in multiple U.S. states.</li></ul><p>Air taxi company Joby Aviation, Inc. (JOBY) said on Wednesday that it has begun flight testing its first Federal Aviation Administration-conforming aircraft N547JX as it seeks to advance in its path to receiving certification for commercial service.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.jobyaviation.com/news-events/press-releases/detail/176/jobys-first-faa-conforming-aircraft-takes-flight">said</a> FAA pilots will visit its California facility later this year to conduct the testing required to validate the aircraft for commercial service following initial testing by the company’s own pilots.</p><h2 class="st-heading-2">U.S. Operations Timeline</h2><p>The announcement comes on the heels of the company recently saying that it stands the chance of beginning early operations this year in multiple U.S. states under the White House-backed eVTOL Integration Pilot Program.</p><p>Joby now sees itself launching in Arizona, Florida, Idaho, New Jersey, New York, North Carolina, Oklahoma, Oregon, Texas and Utah this year. The White House-backed program allows Joby to deploy its air taxis in the U.S. before receiving certification from the Federal Aviation Administration.</p><h2 class="st-heading-2">FAA Certification Efforts</h2><p>However, Joby continues to eye the FAA certification.</p><p>“Seeing this aircraft fly means everything to our team. It’s the validation of years of hard work and marks our entry into the final phase of bringing this aircraft to market,” said Didier Papadopoulos, President of Aircraft OEM at Joby.</p><p>The aircraft in question is the first of a fleet currently in production to support the testing, Joby said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around JOBY stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/JOBY">JOBY stock</a> has gained 70% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-investors-await-details-of-upcoming-r2-amid-rising-price-speculation/cZdMV6cRIBY">Rivian Investors Await Details Of Upcoming R2 Amid Rising Price Speculation</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the logo of Joby Aviation, Inc. is displayed on a smartphone screen with a stock market chart in the background, on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Joby Aviation Makes First Steps Towards FAA Certification Of Aircraft

The company said FAA pilots will visit its California facility later this year to conduct the testing required to validate the aircraft for commercial service.

<ul class="summary-bullets"><li>MTN reported Q2 fiscal 2026 net income attributable to Vail Resorts of $210.0 million compared to $244.4 million in the prior year.&nbsp;</li><li>Due to the persistent, historically challenging weather conditions in the Rockies, which continued to limit terrain availability, the&nbsp;company&nbsp;is reducing its fiscal 2026 guidance, MTN’s CEO noted.&nbsp;</li><li>The company now expects net income attributable to Vail Resorts of $144 million to $190 million for its FY 2026.&nbsp;</li></ul><p>Vail Resorts shares fell in extended hours of trading on Monday after its second quarter revenue of its FY 2026 fell compared to the year-ago quarter&nbsp;and missed analysts’ expectations.&nbsp;</p><p>The company reported total net revenue of $1.08 billion during the reported quarter, down from $1.13 billion it reported year-ago. Analysts, on average, had expected revenue of $1.11 billion, as per from Fiscal.ai data.&nbsp;</p><p>"This has been the most challenging winter across the Rockies that we have ever experienced with the lowest snowfall levels in more than 30 years for our Colorado and Utah resorts, combined with warmer temperatures, resulting in reduced terrain throughout the quarter and into February,” said Rob Katz, Chief Executive Officer, Vail Resorts.&nbsp;</p><p>“While these conditions and the resulting visitation headwinds negatively impacted our quarterly results, we remained focused on the areas within our control. This includes our advanced commitment strategy, continued investments in our resorts and our employees, and progressing key initiatives to optimize visitation, including enhanced marketing and new products,” he added.&nbsp;</p><h2 class="st-heading-2">Q2 2026 Snapshot</h2><p>Vail Resorts reported Q2 fiscal 2026 net income attributable of $210.0 million compared to $244.4 million in the prior year.&nbsp;</p><p>Its resort net revenue decreased $53.2 million, or 4.7%, compared to the prior year, which was primarily driven by the unfavorable weather conditions that impacted visitation and ancillary spending for both local and destination guests during the period.</p><h2 class="st-heading-2">Cuts 2026 Guidance</h2><p>The company now expects net income attributable to Vail Resorts, Inc. of $144 million to $190 million for its FY 2026.&nbsp;</p><p>"Due to the persistent, historically challenging weather conditions in the Rockies, which continued to limit terrain availability, the Company is reducing its fiscal 2026 guidance. While we are lowering our estimates for the fiscal year, given the unprecedented weather in the Rockies, the impact from conditions was mitigated by our advance commitment strategy and resource transformation efforts,” Katz said.&nbsp;</p><h2 class="st-heading-2">Retail Reaction</h2><p>Retail sentiment around MTN stock trended in ‘bearish’ territory amid ‘extremely high’ message volume.</p><p>Shares in the company have been flat so far in 2026.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Vail Resorts shares fell in extended hours of trading on Monday after its second quarter revenue of its FY 2026

Vail Resorts Earnings And 2026 Guidance Cut Kills Investor Optimism

The company reported total net revenue of $1.08 billion during the reported quarter, down from $1.13 billion it reported year-ago.

<ul class="summary-bullets"><li>The White House-backed program allows Joby to deploy its air taxis in the U.S. before receiving certification from the Federal Aviation Administration.</li><li>The selected applications will now progress into the next stage where agreements and operational details will be finalized, the company said.</li><li>Meanwhile, the company continues to look forward to FAA certification.</li></ul><p>Shares of Joby Aviation, Inc. (JOBY) jumped 7% in extended trading hours after the company said that it stands the chance of beginning early operations this year in multiple U.S. states.</p><p>The California-based company, after being selected as a partner in multiple winning applications under the White House-backed Electric Vertical Takeoff and Landing (eVTOL) Integration Pilot Program, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.jobyaviation.com/news-events/press-releases/detail/175/joby-to-begin-u-s-operations-in-2026-under-white-house-air">sees</a> itself launching in Arizona, Florida, Idaho, New Jersey, New York, North Carolina, Oklahoma, Oregon, Texas and Utah this year.</p><h2 class="st-heading-2">What About FAA Certification?</h2><p>The White House-backed program allows Joby to deploy its air taxis in the U.S. before receiving certification from the Federal Aviation Administration. The company noted that the selection has the potential to “significantly accelerate” Joby’s path to commercial service.</p><p>The selected applications will now progress into the next stage, where agreements and operational details will be finalized, the company said. Once contracts are finalized, flights are expected to start within 90 days, it added.</p><p>Meanwhile, the company continues to look forward to FAA certification. Its FAA-conforming aircraft is set to fly “shortly,” the company added.</p><p>The company regularly flies piloted, full-transition flights — taking off vertically, transitioning to wingborne cruise, and returning to vertical landing — as part of a comprehensive real-world flight test program, it added.</p><p>The company further plans to scale production to four aircraft per month in 2027 to meet demand. Joby expanded its site in Marina and Daytona for the purpose.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around JOBY stock rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high levels.</p><p><a href="https://stocktwits.com/symbol/JOBY">JOBY stock</a> has gained 63% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/voyg-shares-decline-on-double-q4-miss-despite-record-2025-backlog/cZdVUXLRIeI">VOYG Shares Decline On Double Q4 Miss Despite Record 2025 Backlog</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

JOBY Shares Rise After-Hours On Potential Air Taxi Launch In Multiple US Cities In 2026

The company sees itself launching air taxis in Arizona, Florida, Idaho, New Jersey, New York, North Carolina, Oklahoma, Oregon, Texas and Utah potentially this year.

Vanguard Index Funds - Vanguard Small Cap ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

VB
Vanguard Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VB News

VBVanguard Small Cap ETF